本研究的目的是探讨程序性细胞死亡蛋白-1 (PD-1) 抑制剂治疗的晚期胃癌 (GC) 患者血清铁水平的影响。我们回顾性分析了接受 PD-1 治疗的 149 名 GC 患者我们中心的抑制剂。分析临床病理特征、实验室数据和临床结果。多变量分析显示东部肿瘤合作组体能状态（ECOG PS）、组织学亚型和基线血清铁水平是总生存期（OS）的独立预后因素，而ECOG PS、多个转移部位和基线血清铁水平是无进展生存期（PFS）的独立预后因素。与血清铁水平 (NSI) 正常的患者相比，基线血清铁水平 (LSI) 较低的患者的中位 OS 和 PFS 显着缩短（中位 OS：7 个月与 14 个月，p = 0.001；中位 PFS：3 与 5月，p = 0.005）。基线 LSI 患者在 PD-1 抑制剂启动后 2 个月 (M2) 的疾病控制率 (DCR) 为 58.3%，而 NSI 患者的疾病控制率为 81.1% (p = 0.005)。基线 LSI 患者 4 个月时的 DCR 为 43.8%，而 NSI 患者为 64.2% (p = 0.017)。LSI 与接受 PD-1 抑制剂治疗的 GC 患者较差的 OS、PFS 和 DCR 相关，并且可能成为预测 PD-1 抑制剂功效的快速有效的生物标志物。© 2023。作者。

The aim of this study was to investigate the influence of serum iron levels in advanced gastric cancer (GC) patients treated with programmed cell death protein-1 (PD-1) inhibitors.We retrospectively reviewed 149 GC patients who were treated with PD-1 inhibitors at our center. Clinicopathological characteristics, laboratory data, and clinical outcomes were analyzed.Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (ECOG PS), histological subtype, and baseline serum iron levels were independent prognostic factors for overall survival (OS), while ECOG PS, multiple metastatic sites, and baseline serum iron levels were independent prognostic factors for progression-free survival (PFS). Patients with baseline low serum iron levels (LSI) had a significantly shorter median OS and PFS compared to patients with normal serum iron levels (NSI) (Median OS: 7 vs. 14 months, p = 0.001; median PFS: 3 vs. 5 months, p = 0.005). Patients with baseline LSI had a disease control rate (DCR) of 58.3% at 2 months after PD-1 inhibitor initiation (M2), compared to 81.1% in patients with NSI (p = 0.005). Patients with baseline LSI had a DCR of 43.8% at 4 months, compared to 64.2% in patients with NSI (p = 0.017).LSI was associated with worse OS, PFS, and DCR in GC patients treated with PD-1 inhibitors and might be a quick and efficient biomarker to predict the efficacy of PD-1 inhibitors.© 2023. The Author(s).